Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new agreement to develop drugs for ...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May, as organisations ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Pfizer's Ibrance has become the first CDK4/6 inhibitor to be approved by the FDA for a challenging subtype of breast cancer ...

HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...